Skip to main content

CROSSBOSS™

Coronary CTO Crossing Catheter

The CROSSBOSS Catheter allows you to treat complex lesions safely, with maximum efficiency and success.
Atraumatic, rounded tip reduces risk of perforation.
Hydrophilic coated, multi-wire coiled shaft provides precise turn-for-turn response.
Fast-Spin torque device allows rapid rotation of the catheter to facilitate crossing.
play icon
View the CROSSBOSS and STINGRAY Re-Entry System procedure animation.
The CROSSBOSS Catheter allows you to treat complex lesions safely, with maximum efficiency and success.
Atraumatic, rounded tip reduces risk of perforation.
Hydrophilic coated, multi-wire coiled shaft provides precise turn-for-turn response.
Fast-Spin torque device allows rapid rotation of the catheter to facilitate crossing.
View the CROSSBOSS and STINGRAY Re-Entry System procedure animation.

Designed to quickly and safely deliver a guidewire via the true lumen or subintimal pathways, CROSSBOSS Catheter gives you total access to coronary chronic total occlusions.

Key Resources

Explore

Specifications

Ordering Information

UPN #Catalog NumberProduct Name/DescriptionC Code
H749M2000A0M-2000-ACROSSBOSS CatheterC1725
H749393120SR039312-0SRSTINGRAY LP DeviceC1725
H749M3004A0M-3004-ASTINGRAY Guidewire 300 cmC1769
H749M3010A0M-3010-ASTINGRAY Extension WireC1769
H749M3012A0M-3012-ASTINGRAY Guidewire 185 cmC1769

Clinical Information

FAST-CTO Trial

Facilitated Antegrade Steering Technique in Chronic Total Occlusions

The FAST-CTO trial demonstrated the safety and efficacy of the CROSSBOSS and STINGRAY Coronary CTO Crossing and Re-Entry devices to recanalize coronary CTOs in comparison to historical controls.

  • Multi-center, non-randomized US IDE study
  • 147 patients in 16 centers

Safe and Effective

Use of the CROSSBOSS and STINGRAY Crossing and Re-Entry devices result in a high technical success, 77%, without increasing complications.1

Reduced Procedure Time

Procedural success was improved with a 28.1% reduction in mean procedure time (minutes) as well as a reduction in fluoroscopy time.1

Primary Endpoints
Secondary Endpoint

Principal Investigators

Patrick Whitlow MD, William Lombardi MD, Michael Wyman MD, Craig Thompson MD

Cleveland Clinic, PeaceHealth Medical Center/St Joseph Hospital, Torrance Memorial Medical Center, Yale University School of Medicine

 
MPCI banner
 
Top